SEC Form 4 · accession 0001636282-26-000100
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott L Burrows
Officer — Chief Financial Officer
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 9:32 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 3, 2026 | M | 7,500 | $14.50 | A | 105,494 | D | |
| Common StockF2 | Aug 3, 2026 | S | 5,100 | $95.21 | D | 100,394 | D | |
| Common StockF3 | Aug 3, 2026 | S | 2,300 | $96.30 | D | 98,094 | D | |
| Common StockF4 | Aug 3, 2026 | S | 100 | $97.10 | D | 97,994 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $14.50 | Aug 3, 2026 | M | 7,500 | D | — | Sep 1, 2033 | Common Stock | 7,500 | 344,857 | D |
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.84 to $95.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.85 to $96.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
- F5This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.